Literature DB >> 3933519

Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl.

J B Robinson.   

Abstract

The enantiomers of amphetamine, N-methylamphetamine and deprenyl were studied, using a solubilised rat liver mitochondrial monoamine oxidase (MAO) preparation, as competitive inhibitors of MAO-A and MAO-B (5-hydroxytryptamine and beta-phenylethylamine as substrate respectively). Only in the case of deprenyl enantiomers inhibiting MAO-B was a preference shown towards the [R]-configuration enantiomer justifying the use of [R]-(-)-deprenyl (as compared to the racemate) for the specific inhibition of MAO-B. Recalculation of the observed Ki values in terms of the base form of the inhibitor indicated that the activity of all enantiomers fell within a narrow, approximately 25-fold range when inhibiting MAO-B. The selectivity of inhibition of MAO-B by [R]-(-)-deprenyl cannot therefore be attributed to any specific structural features of the MAO-B isoenzyme form but rather to a lack of affinity of this enantiomer towards MAO-A.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933519     DOI: 10.1016/0006-2952(85)90201-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  19 in total

1.  Substituted methcathinones differ in transporter and receptor interactions.

Authors:  Amy J Eshleman; Katherine M Wolfrum; Meagan G Hatfield; Robert A Johnson; Kevin V Murphy; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2013-04-10       Impact factor: 5.858

Review 2.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

3.  Effects of methamphetamine isomers on d-methamphetamine self-administration and food-maintained responding in male rats.

Authors:  M T Bardo; E D Denehy; L R Hammerslag; L P Dwoskin; B E Blough; A Landavazo; J Bergman; S J Kohut
Journal:  Psychopharmacology (Berl)       Date:  2019-07-26       Impact factor: 4.530

4.  Differences between dextroamphetamine and methamphetamine: behavioral changes and oxidative damage in brain of Wistar rats.

Authors:  Dayane D da-Rosa; Samira S Valvassori; Amanda V Steckert; Camila O Arent; Camila L Ferreira; Jéssica Lopes-Borges; Roger B Varela; Edemilson Mariot; Felipe Dal-Pizzol; Monica L Andersen; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2011-08-20       Impact factor: 3.575

5.  Effect of reserpine on the brain uptake of carbon 11 methamphetamine and its N-propagyl derivative, deprenyl.

Authors:  O Inoue; S Axelsson; H Lundqvist; L Oreland; B Långström
Journal:  Eur J Nucl Med       Date:  1990

Review 6.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

Review 7.  The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango.

Authors:  Harald H Sitte; Michael Freissmuth
Journal:  J Neurochem       Date:  2009-11-05       Impact factor: 5.372

8.  Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies.

Authors:  Angélica Fierro; Mauricio Osorio-Olivares; Bruce K Cassels; Dale E Edmondson; Silvia Sepúlveda-Boza; Miguel Reyes-Parada
Journal:  Bioorg Med Chem       Date:  2007-05-22       Impact factor: 3.641

9.  Interactions of D-amphetamine with the active site of monoamine oxidase-A.

Authors:  Rona R Ramsay; Dominic J B Hunter
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 10.  Amphetamine, past and present--a pharmacological and clinical perspective.

Authors:  David J Heal; Sharon L Smith; Jane Gosden; David J Nutt
Journal:  J Psychopharmacol       Date:  2013-03-28       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.